ISH staining of MALAT1 in HER2 positive breast cancer patients (n = 58) treated with trastuzumab showed that patients with high expression of MALAT1 were resistant to trastuzumab treatment (Fig. 2E). Here, ERBB2 is linked to breast carcinoma.